Exploratory development for DAZ gene content in pregnancy serum as a new prenatal screening indicator of Down's syndrome
AIM:To discuss the feasibility of DAZ gene content in pregnancy serum as a new prenatal screening indicator of Down's syndrome. METHODS: Cell-free fetal DNA in maternal serum was isolated from 70 samples in early pregnancy (7-12 wk). Samples consisted of 10 women carrying male trisomy 21 fetuses, 30 carrying euploid male fetuses, and 30 carrying female fetuses. TaqMan probe real-time quantitative PCR was used to detect both DAZ gene on Y chromosome and β-actin gene of the mothers and the fetuses. RESULTS: Down's syndrome pregnancies exhibit 2.2-hold higher levels of maternal serum cell-free fetalDNA compared with matched controls. None of the samples from women carrying female fetuses had detectable Y-chromosomal signals. CONCLUSION: Detection of cell-free fetal DNA in maternal serum by TaqMAN probe real-time quantitative polymerase chain reaction (real-time quantitative PCR) and on the basis of its amount is a potential prenatal screening marker for trisomy 21.
NETL
NSTL
万方数据
维普
